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ABSTRACT
Background: The number of patients using second-
line antiretroviral therapy (ART) has increased over
time. In Ethiopia, 1.5% of HIV infected patients on ART
are using a second-line regimen and little is known
about its effect in this setting.
Objective: To estimate the rate and predictors of
treatment failure on second-line ART among adults
living with HIV in northwest Ethiopia.
Setting: An institution-based retrospective follow-up
study was conducted at three tertiary hospitals in
northwest Ethiopia from March to May 2015.
Participants: 356 adult patients participated and 198
(55.6%) were males. Individuals who were on second-
line ART for at least 6 months of treatment were included
and the data were collected by reviewing their records.
Primary outcome measure: The primary outcome
was treatment failure defined as immunological failure,
clinical failure, death, or lost to follow-up. To assess our
outcome, we used the definitions of the WHO 2010
guideline.
Result: The mean±SD age of participants at switch was
36±8.9 years. The incidence rate of failure was 61.7/1000
person years. The probability of failure at the end of 12
and 24 months were 5.6% and 13.6%, respectively. Out
of 67 total failures, 42 (62.7%) occurred in the first
2 years. The significant predictors of failure were found
to be: WHO clinical stage IV at switch (adjusted HR
(AHR) 2.1, 95% CI 1.1 to 4.1); CD4 count <100 cells/
mm3 at switch (AHR 2.0, 95% CI 1.2 to 3.5); and weight
change (AHR 0.92, 95% CI 0.88 to 0.95).
Conclusions: The rate of treatment failure was highest
during the first 2 years of treatment. WHO clinical stage,
CD4 count at switch, and change in weight were found to
be predictors of treatment failure.
INTRODUCTION
HIV has been a global challenge for the past
three decades. In 2013, 35 million people
were living with HIV worldwide.1
Sub-Saharan Africa carries the highest
burden with an estimated 24.7 million
people living with HIV, nearly 71% of the
global total.1 2 In Ethiopia the HIV preva-
lence among adults age 15–49 years was
1.5%,3 and in 2014 the estimated incidence
was 35 002 cases with an overall estimated
death toll of 52 405.
Since 1995, antiretroviral therapy (ART)
has saved the lives of millions globally and
has substantially decreased morbidity and
mortality in people living with HIV/AIDS
(PLWHA).4 Since ART ﬁrst became freely
available in Ethiopia in 2005 until 2013,
death due to HIV/AIDS has decreased by
63%.2 Based on the 2014 report released
from the United Nations Program on HIV/
AIDS (UNAIDS), globally as many as
13 950 296 people were accessing ART.2 For
the year 2013-14, the Federal Ministry of
Strengths and limitations of this study
▪ The study involved three diverse hospitals, and
had a follow-up period longer than several other
similar studies.
▪ The data were collected in a retrospective fashion
using secondary sources, with resulting
incompleteness.
▪ Information bias may have occurred due to
under-reporting of clinical conditions that consti-
tute clinical failure, and missing laboratory
results which may have categorised patients as
having immunological failure.
▪ Considering treatment failure as a composite
outcome for immunological failure, clinical
failure, death and lost to follow-up might over-
estimate the rate of treatment failure.
▪ Use of immunological and clinical criteria lacks
both sensitivity and specificity to detect real
treatment failure (ie, virological failure) and
might underestimate treatment failure.
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Health of Ethiopia (FMOH) reported that 1047 health
facilities were providing ART, 805 948 PLWHA were
enrolled in HIV/AIDS care, 492 649 PLWHA had started
ART, and 344 344 people were using ART. Of these ART
users, 1.5% were on second-line treatment. The Amhara
regional state in northwest Ethiopia comprises the
highest proportion of ART users, with 102 088
individuals.5
Most patients begin treatment for HIV/AIDS on a
standard ﬁrst-line regimen. The ﬁrst-line treatment con-
sists of a combination of two nucleoside/nucleotide
reverse transcriptase inhibitors (NRTI) with one non-
nucleoside reverse transcriptase inhibitor (NNRTI).
Should failure of ﬁrst-line treatment occur, a second-line
treatment is implemented, utilising two NRTIs not previ-
ously used in ﬁrst-line treatment, as well as one additional
protease inhibitor (PI).6 7 Treatment failure of the initial
ﬁrst-line ART regimen is a common, though not inevit-
able, event.8 9 According to a study done in South Africa,
the rate of ﬁrst-line treatment failure was 13%,10 and
another study by Roose et al reported an overall treatment
failure rate of 46%.11 Second-line regimens are used after
failure of ﬁrst-line regimens, as measured by the patient’s
CD4 cell count, HIV viral load, or clinical features.
Though frequently effective, standard ﬁrst-line regimens
do not work for everyone, particularly if they are infected
with a drug-resistant strain of the virus12 and/or have
poor adherence.13 14 Other predictors for treatment
failure of ﬁrst-line treatments include: older age,10 15
male sex,10 11 16 severe malnutrition,10 17 anaemia9 10 18
low baseline CD4 cell count,10 16 19 advanced baseline
WHO clinical stage,16 20 21 longer duration of ART
intake,22 and a negative change in body weight.23
According to different studies, switching patients after
failure of ﬁrst-line regimens reduces mortality,24
increases viral suppression, improves immune reconstitu-
tion,25 26 increases life expectancy,27 and decreases drug
resistance.28 Though the number of patients being
switched has been increasing over time,9 24 it remains
small29 due to delays in switching from ﬁrst-line therapy
and30 31 challenges in drug availability. Little is known
about the success of these second-line therapies.
Although some studies have been conducted in other
sub-Saharan countries, there is little information about
second-line ART failure in Ethiopia.
Therefore, this study aimed to determine the rate and
predictors of treatment failure on second-line ART. This
research also evaluated the progress in Ethiopia’s strat-
egy against HIV/AIDS, and is to be used to inform
respective stakeholders about the current state of
second-line ART users and to assist in planning for the
possible need of future, third-line regimens.
METHODS
Study design
An institution-based retrospective follow-up study was
conducted in three large hospitals in the Amhara
regional state, northwest of Ethiopia’s capital city, Addis
Ababa (University of Gondar Teaching Hospital, Felege
Hiwot referral Hospital, and Debretabor Hospital).
Settings
University of Gondar Teaching Hospital HIV care clinic
is located in North Gondar administrative zone, Amhara
National Regional state, which is about 750 km north-
west of Addis Ababa. Currently, University of Gondar
Teaching Hospital is serving more than ﬁve million
people in the North Gondar zone and peoples of the
neighbouring zones. Since 2005, when the hospital
initiated ART, 7581 adults and 738 paediatrics patients
have enrolled. Currently 4891 adults are actively being
treated.
The second study area is Felege Hiwot Referral
Hospital, located in Bahirdar, Amhara National Regional
State, Ethiopia. Bahirdar is the capital city of Amhara
National Regional State and it is located 562 km from
Addis Ababa and 180 km from Gondar. The hospital
serves a catchment population of 5–7 million. Since the
initiation of ART in 2005, 16 314 adults and 1383 paedi-
atrics patients have been enrolled. Currently 5401 adults
are actively being treated.
The third study area was Debretabor Hospital which is
located in Debretabor 665 km from Addis Ababa. It
serves a catchment population of around 2 million. In
addition to other services, Debretabor Hospital is cur-
rently providing HIV chronic care (both pre-ART and
ART). Since 2005, when the hospital started ART, 9859
adults and 698 paediatrics patients have been enrolled.
Currently 2401 adults are being treated.
Participants
The study population included all HIV positive adults,
age 15 years and above, who started second-line ART at
University of Gondar, Debre Tabor or Felge Hiwot refer-
ral hospitals. Patients who switched to a second-line
treatment in the years between September 2006 and
October 2014 were included and followed until April
2015 (ﬁgure 1). To be included, patients must have
been on second-line ART therapy for at least 6 months.
This inclusion criterion was based on the WHO treat-
ment guideline which recommends allowing at least
6 months of treatment with a given regimen before diag-
nosing treatment failure.7 The study participants were
managed using different treatment guidelines due to
guideline updates over time. The drugs they were
taking, the deﬁnition of treatment failure, and the cri-
teria used to switch them to a second-line treatment are
variable. As per the current recommendation, NRTIs
such as lamivudine (3TC), zidovudine (AZT) and teno-
fovir (TDF); NNRTIs such as efavirenz (EFV) and nevira-
pine (NVP); and protease inhibitors (PI) such as
atazanavir/ritonavir (ATV/r) and lopinavir/ritonavir
(LPV/r), are being used. For ﬁrst-line treatment a com-
bination of two NRTIs with one NNRTI, and for second-
line treatment two NRTIs with one PI,6 7 are being used.
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After baseline data are collected from patients, the CD4
count is repeated every 6–12 months and viral load is
determined when there is suspicion of treatment
failure.6
Data were collected by four health ofﬁcers and ﬁve
BSc nurses who had experience of working in ART
clinics. All data collectors were trained in the data collec-
tion process which included a standardised data extrac-
tion checklist prepared in English. Trained data
collectors, other than the investigators, reviewed and
extracted data from patient charts and registries about
sociodemographic characteristics (age, sex), clinical
characteristics (WHO clinical staging, CD4 count at
switch of ART, length of time on ﬁrst-line ART, change
in weight, presence of opportunistic infection (OI), cal-
endar year of starting second-line ART), and treatment
related factors (drug regimen, OI prophylaxis,
cotrimoxazole preventive therapy (CPT), isoniazid
(INH) prophylaxis, history of ﬁrst-line modiﬁcation,
treatment duration, number of NRTIs tried, and drug
side effect). Additionally, for the cards that had incom-
plete information, computer databases were used to sup-
plement the information where possible.
To control the data quality, a data extraction checklist
was pre-tested for consistency of understanding the
review tools and completeness of data items. The neces-
sary adjustments were made on the ﬁnal data extraction
format and the ﬁlled formats were checked daily by the
supervisors. Investigators were involved in the supervi-
sion of the data collection. The patients’ names and
their unique ART numbers were not included during
data collection to ensure privacy. To protect patient
identity, supervisors linked the patient’s card number
with a study identiﬁcation number.
Second-line regimen was deﬁned as a boosted
PI-based regimen, following a ﬁrst-line regimen of one
NNRTI and two NRTIs. According to the WHO criteria,
clinical failure was deﬁned as a new or recurrent clinical
event indicating severe immunodeﬁciency: WHO clinical
stage 4 conditions (eg, Kaposi’s sarcoma, pneumocystis
pneumonia) and certain WHO clinical stage 3 condi-
tions (eg, pulmonary tuberculosis (TB), severe bacterial
infections) after 6 months of effective treatment.
Immunological failure was deﬁned as fulﬁlment of at
least one of the following criteria: follow-up CD4 count
at or below baseline values, a 50% fall from peak value
while on treatment, or persistent CD4 levels below
100 cells/mm3. Death was deﬁned as the recorded death
in a patient who was on second-line ART. Transferred
out referred to patients who were transferred to other
healthcare facilities. Transferred in referred to patients
who were transferred from other facilities and accepted
by one of the three study hospitals. Loss to follow-up
(LTFU) was deﬁned as a patient who had not received
repeat ART for a period of 3 months or longer, and was
not yet classiﬁed as ‘dead’ or ‘transferred-out’. In the
setting of HIV drug resistance, genotyping and follow-up
viral load of patients on second-line treatment is not
being done. Because of this, even if it is less reliable, we
assessed treatment failure by using the available informa-
tion of clinical and immunological criteria. In this study,
our primary outcome was treatment failure, deﬁned as a
composite outcome of immunological failure, clinical
failure, death and LTFU. If a patient had one of the
four outcomes, he/she was considered to have had treat-
ment failure. As shown by other studies, most patients
who were categorised as LTFU ended up having treat-
ment failure and subsequently died after being
lost1 23 32 33 due to rebound viral replication following
their treatment discontinuation. Because of these
reasons we considered LTFU as a treatment failure. In
the setting, since there is only one regional laboratory to
undertake viral load determination for more than 20
million people, viral load was not performed for all
patients. We did not have any follow-up viral load data to
assess virological failure after switching treatment. The
reported viral load data are documented at the time of
switch to diagnose ﬁrst-line treatment failure. Regarding
the deﬁnition of virological failure of ﬁrst-line treatment,
there was no single deﬁnition. Since our participants
were switched over a variable period of time, there were
guideline changes and because of that the deﬁnition of
virological failure also varied from participant to partici-
pant. Therefore, we just recorded the presence of docu-
mented virological failure at the time of switch
(provided that the deﬁnitions were different from time
to time). Some patients might switch to second-line
treatment based on their clinical and immunological
condition regardless of the viral load. Change in weight
was deﬁned as the difference between the participant’s
last weight and the baseline weight at switch to second-
line ART.
Figure 1 Schematic representation of the sampling
procedure of HIV positive adults on second-line antiretroviral
therapy at University of Gondar, Debretabor, and Felege
Hiwot referral hospitals, 1 September 2006 to 8 April 2015.
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The data were entered into Epi info V.7 and transferred
to STATAV.12.0 for analysis. Descriptive and summary sta-
tistics were performed. The rate of failure of the compos-
ite outcome (treatment failure) and each of the other
potential outcomes separately were observed. Person-time
at risk was measured starting from the time of switch to a
second-line regimen until each patient ended the
follow-up. Patients who switched between September
2006 and October 2014 were included in the analysis.
Life table analysis was used to estimate the cumulative
failure of patients and log rank tests were used to
compare failure curves between the different categories
of the explanatory variables. Patients who transferred out
or remained alive in care at the end of follow-up were
considered as censored observations. Schoenfeld residuals
test (both global and scaled) and graphical methods were
used to check the Cox proportional hazard assumption.
Both bivariable and multivariable Cox proportional
hazards models were used to identify predictors of
failure. Variables having p values of 0.2 or less in the
bivariable analysis were ﬁtted into the multivariable
model. The 95% CI of HR was computed and variables
having a value of p<0.05 in the multivariable Cox propor-
tional hazards model were considered to be signiﬁcantly
associated with treatment failure.
RESULTS
Baseline characteristics
Of the 356 participants, 198 (55.6%) were male with a
mean±SD age of 36±8.9 years; 167 (46.9%) of the parti-
cipants were between 30 and 39 years of age.
Characteristics during first-line treatment
During the start of ﬁrst-line treatment, 306 (86%) parti-
cipants were at WHO clinical stage III or IV and 213
(59.8%) had CD4 counts below 100 cells/mL with a
median CD4 count of 78.5 cells/mL (interquartile
range (IQR) 37−151). One hundred and seventy-six
(49.4%) of the participants were eligible to start ART by
both clinical and immunological (CD4 count) criteria.
In regard to NRTIs, at initiation of ﬁrst-line ART, 162
(45.5%) of the study participants were on zidovudine
(AZT), 133 (37.4%) were on stavudine (d4T), and 61
(17.1%) were on tenofovir (TDF). Two hundred and
ﬁfty-seven (72.2%) of the study participants were taking
NVP as an NNRTI drug.
For 118 (33.2%) participants, the ﬁrst drug regimen
was modiﬁed before switching to second-line ART, and
among them, 102 (86.4%) patients went through only
one modiﬁcation. In 82 (70.7%) participants, drug side
effects were the reason for regimen modiﬁcations. TB
comorbidity was the reason for modiﬁcation in 24
(20.7%) participants. The median time of stay on ﬁrst-
line regimen was 42.6 months (IQR 26.3−64.1) months.
One hundred and twenty-one (34%) participants had a
previous history of TB treatment before switching to
second-line ART.
Characteristics during and after switch to second-line
treatment
At the start of second-line ART, 172 (48.3%) of the
patients were at WHO clinical stage III. The median
CD4 count at switch was 79 cells/mm3 (IQR 37−155) for
all participants. The mean±SD weight of participants at
the start of second-line ART was 52.5±10.8 kg. In regard
to NRTIs, 206 (57.9%) of the patients were taking TDF
based second-line regimens. For PIs, 289 (81.2%) were
taking lopinavir boosted with ritonavir (table 1).
The reasons for patients switching to second-line treat-
ments were virological failure, immunological failure,
clinical failure and drug toxicity of ﬁrst-line treatment.
The most common causes were a combination of
Table 1 Sociodemographic, clinical and immunological
characteristics of HIV positive adults at start of second-line
ART at University of Gondar, Debretabor, and Flege Hiwot
referral hospitals, September 2006 to April 2015
Variable Category Frequency %
Age (years) 15–29 78 21.9
30–39 167 46.9
40–49 82 23.0
>50 29 8.2
Sex Male 198 55.6
Female 158 44.4
Marital status Unmarried 154 43.3
Married 157 44.1
Not recorded 45 12.6
Residence Urban 260 73.0
Rural 76 21.4
Not recorded 20 5.6
WHO clinical stage
at switch
Stage I/II 127 35.7
Stage III 172 48.3
Stage IV 57 16.0
Number of changed
NRTI at switch
None 19 5.3
One 217 61.0
Two 120 33.7
Protease inhibitor Lopinavir/
ritonavir
289 81.2
Atazanavir/
ritonavir
64 18.0
Nelfinavir 3 0.84
NRTI backbone at
switch
Tenofovir 206 58.0
Abacavir 102 28.6
Zidovudine 41 11.5
†Others (d4t,
ddi)
7 2.0
CD4 count at
switch
<100 cells/
mm3
222 62.4
≥100 cells/
mm3
134 37.6
CPT Yes 306 86.0
No 50 14.0
INH prophylaxis Yes 33 9.3
No 323 90.7
Total 356 100.00
ART, antiretroviral therapy; CPT, cotrimoxazole preventive
therapy; d4t, stavudine; ddi, didanosine; INH, isoniazid; NRTI,
nucleoside reverse transcriptase inhibitors.
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immunological and virological failure (40.5%), followed
by immunological failure only (37.1%), and a combin-
ation of clinical, immunological and virological failure
(8.9%). The less common reasons were immunological
and clinical failure in combination, drug toxicity only,
virological failure only, and clinical failure only (6.5%,
4.8%, 1.4%, and 0.8%, respectively) (table 2).
Two hundred and ten (59%) of the participants had a
recorded viral load before the start of second-line treat-
ment, of which 177 (84.3%) had virological failure; 331
(93%) of the participants also had an immunological
failure at the start of second-line ART (table 2). During
the follow-up period, 24 (6.7%) participants developed
opportunistic infections other than those classiﬁed in the
clinical failure category. Eighteen (5.1%) of the partici-
pants modiﬁed their second-line treatment, of whom 12
(66.7%) modiﬁed due to drugs being out of stock. Drug
adverse effect were recorded in 23 (6.5%) participants.
Treatment failure of second-line treatment
Study subjects were followed for a median follow-up
period of 32.3 months (IQR 15.4−53.2) after switching
to second-line ART, with a total observation period of
1085.11 person-years. A total of 67 patients developed
treatment failure, of which 19 (28.3%) and 42 (62.7%)
were reported within the ﬁrst and second years of
follow-up, respectively. Among the total failures, 24
(35.8%) were immunological failure, 21 (31.3%) were
deaths, 11 (16.4%) were clinical failure, and 11 (16.4%)
were categorised as lost to follow-up.
The incidence of treatment failure of second-line
treatment was 61.7 (95% CI 48.6 to 78.5) per 1000
person years of observation. From this, immunological
failure, clinical failure, death, and lost to follow-up were
22.1, 10, 19, and 10 per 1000 person years, respectively.
Considering the composite outcome, the cumulative
probabilities of failure at 12 months was 5.6% (95% CI
3.6% to 8.7%), at 24 months it was 13.6% (95% CI 10.2%
to 18%), at 60 months it was 23.5% (95% CI 18.3% to
29.8%), and at 96 months it was 42.3% (95% CI 29.7% to
57.5%) (ﬁgure 2). At the end of 24 and 60 months, the
probability of failure for those who had CD4 counts
<100 cells/mm3 at switch was 16.1% and 27.2%,
respectively.
Predictors of second-line treatment failure
In the multivariable Cox regression analysis, the inde-
pendent predictors of treatment failure of second-line
ART were: a negative change in weight, a CD4 count
<100 cells/mm3 at the start of second-line ART, and
WHO clinical stage IV at the start of second-line ART
(table 3). Being at WHO stage IV compared to WHO
stage I/II was associated with a 2.1 times higher risk
(adjusted HR (AHR) 2.1, 95% CI 1.1 to 4.1) of treat-
ment failure.
A change in weight from initiation of the study to the
end of follow-up had an inverse relation with failure. For
a unit increase in weight in kilograms, the risk of treat-
ment failure decreased by 8.4% (AHR 0.916, 95% CI
0.88 to 0.95). A CD4 count <100 cells/mm3 at the start
of second-line ART increased the risk of developing
treatment failure by 2.0 times as compared to a CD4
count >100 cells/mm3 (AHR 2, 95% CI 1.2 to 3.5).
Table 2 Reasons for switching to second-line ART, at
University of Gondar, Debretabor, and Flege Hiwot referral
hospitals, 1 September 2006 to 8 April 2015
Reasons for switching Frequency %
Immunological and virological
failure
144 40.5
Immunological failure only 132 37.1
Clinical, immunological and
virological failure
32 8.9
Immunological and clinical failure 23 6.5
Drug toxicity only 17 4.8
Virological failure only 5 1.4
Clinical failure only 3 0.8
Total 356 100.00
ART, antiretroviral therapy.
Figure 2 Kaplan-Meier failure curve showing hazard from treatment failure of HIV positive adults on second-line antiretroviral
therapy at University of Gondar, Debretabor, and Felege Hiwot referral hospitals, September 2006 to April 2015.
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DISCUSSION
This study aimed to measure predictors of treatment
failure of adult patients on second-line ART. The overall
incidence of failure was 61.7 (95% CI 48.6 to 78.5) per
1000 person years, with the majority of failures (62.8%)
occurring in the ﬁrst 2 years of follow-up. This study
found the signiﬁcant predictors of treatment failure of
second-line ART to include: a negative change in weight
during the study period, a CD4 count <100 cells/mm3 at
switch, and patients categorised as WHO clinical stage
IV at switch.
The incidence of failure in this study is in agreement
with studies conducted in Cambodia and Thailand and
a meta-analysis done in developing countries.22 25 34 35
However, the incidence of failure found by this study is
lower than a multicentred study conducted in Asia and
Africa, which found an overall incidence of 195 per
1000 person-years.36 The reason for this might be due to
the difference in follow-up periods. Because most fail-
ures occur soon after the switch is made to a second-line
therapy, a shorter follow-up period is likely to ﬁnd a
higher probability of failure when compared to a study
with a longer follow-up period. Another explanation
may be differences in the diagnostic criteria for treat-
ment failure. In another study, viral load was used to
assess treatment failure, in addition to other criteria.
Viral load increases before other immunologic and clin-
ical markers, which can shorten the time to diagnosis.
Due to its sensitivity, patients who have no immuno-
logical and clinical failure may already have virological
failure. Finally, this study was prospective which allowed
the investigators to ensure strict follow-up and diagnosis
of failure criteria, unlike our current study which was
retrospective.
In our study, being at WHO clinical stage IV at the
time of switch to second-line therapy was one of the sig-
niﬁcant predictors of treatment failure. Patients who
were at WHO clinical stage IV were 2.1 times more at
risk of treatment failure than those patients who were at
WHO clinical stage I/II. This result is consistent with
studies done in Malawi and sub-Saharan Africa.13 37 This
ﬁnding is likely due to the fact that patients who present
with advanced disease stage are at higher risk of drug
resistance, viral mutation and death. Additionally, having
a comorbid advanced opportunistic disease which cate-
gorises a patient as WHO IV may lead to drug interac-
tions between the treatment for OI and the ART which
may further compromise their immunity. This may nega-
tively affect their response to treatment after switch.
A CD4 count below 100 cells/mm3 was also a predictor
of failure. A CD4 count <100 cells/mm3 at baseline
increased the risk of developing treatment failure by 2.0
times compared to a CD4 count ≥100 cells/mm3. This
ﬁnding is consistent with studies done in Thailand,
Malawi, and South Africa.13 36 38 This might be due to
the fact that patients with a very low CD4 count are
more likely to have different opportunistic infections
and the added burden of these diseases further compli-
cates their response. This likely increases the possibility
of treatment failure and/or death.
Table 3 Multivariable Cox regression analysis of predictors of second-line ART failure of adult HIV positive patients at
University of Gondar, Debretabor, and Felege Hiwot referral hospitals, September 2006 to April 2015
Treatment failure
Crude HR (95% CI) Adjusted HR (95% CI)Variable Yes No
Age (years)
15–29 17 61 1 *
30–39 26 141 0.7 (0.4 to 1.3) 0.7 (0.4 to 1.4)
40–49 14 68 0.8 (0.4 to 1.5) 0.9 (0.4 to 1.8)
≥50 10 19 1.8 (0.8 to 4.0) 1.7 (0.8 to 3.9)
INH prophylaxis
Yes 3 30 2.3 (0.7 to 7.2) 1.7 (0.5 to 5.7)
No 64 259 1
Weight change (per 1 kg increase) 0.9 (0.89 to 0.96) 0.916 (0.88 to 0.95)
WHO clinical staging at switch
I/II 20 107 1
III 29 143 0.8 (0.5 to 1.5) 1.0 (0.6 to 1.8)
IV 18 39 1.6 (0.8 to 3.0) 2.1 (1.1 to 4.1)
CD4 cell count
<100 cells/mm3 47 175 1.8 (1.0 to 2.9) 2 (1.2 to 3.5)
≥100 cells/mm3 20 114 1
NRTI‡ at first-line ART start
Stavudine (d4T) 29 104 1
Zidovudine (AZT) 15 137 0.9 (0 0.5 to 1.5) 0.9 (0.5 to 1.6)
Tenofovir (TDF) 13 48 1.8 (0.9 to 3.6) 1.9 (0.9 to 3.8)
*Non-significant from the multivariable Cox regression.
ART, antiretroviral therapy; AZT, as lamivudine (3TC), zidovudine; INH,isoniazid; NRTI, nucleoside reverse transcriptase inhibitors.
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Change in weight was the other signiﬁcant predictor
of failure. For a unit increase in weight in kilograms, the
risk of treatment failure decreased by 8.4%. This can be
explained by understanding weight gain as an indicator
of good response to treatment and having a positive
effect for immunity.13 Decreasing weight may cause OI
and vice versa. In most of cases weight change is linked
to the clinical condition of the patient.
While the strengths of this study include the involve-
ment of three diverse hospitals and a follow-up period
longer than several other similar studies, it also has lim-
itations. First, the data were collected in a retrospective
fashion using secondary sources with resulting incom-
pleteness, especially where treatment adherence of the
participants was not assessed. Adherence to treatment is
a known predictor of treatment response, and lack of
adherence data is a limitation of the current study.
Additionally, information bias may have occurred due to
under-reporting of clinical conditions that constitute
clinical failure, and missing laboratory results which may
have categorised patients as having immunological
failure. Use of immunological and clinical criteria lacks
both sensitivity and speciﬁcity to detect real treatment
failure (ie, virological failure) and it might underesti-
mate treatment failure. Finally, regarding treatment
failure as a composite outcome for immunological
failure, clinical failure, death and lost to follow-up might
overestimate the rate of treatment failure.
CONCLUSIONS
The rate of treatment failure was high during the ﬁrst
2 years after switching to a second-line regimen. The sig-
niﬁcant predictors of second-line ART therapy failure
were: being at WHO clinical stage IV; having a CD4
count <100 cells/mm3 at the time of switching to a
second-line treatment; and a negative change in weight.
Therefore, an alternative third-line ART regimen should
be considered for those who are on a failing second-line
regimen. This study may be generalised to patients who
are using second-line ART in the Amhara region.
Acknowledgements We would like to thank the University of Gondar, Debre
Tabor and Felege Hiwot referral hospitals administrative bodies, data clerks
and card room workers for their cooperation and permission to conduct the
study. We are grateful to the University of Gondar for the financial support as
well as the data collectors who participated in this study for their
commitment. The authors also would like to extend their gratitude to Anna
Bazinet and Khathrine Pfizenmaier for their manuscript editing.
Contributors ATT conceived the idea and the research designed by ATT, MW
and TA. ATT coordinated the process. ATT and TA analysed the data. ATT,
MW, TA and KAA wrote the paper. All authors read and approved the final
manuscript.
Funding The financial backing of this research was provided by the University
of Gondar as a grant to its staff.
Competing interests None declared.
Ethics approval Ethical clearance was obtained from the Institutional Review
Board of University of Gondar. A letter of support and a permission letter
were obtained from the Amhara Regional State Health Bureau and the
hospital’s administration, respectively. Care was taken to keep all patient
information confidential. Since we used secondary sources, informed consent
was waived.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement All data supporting our findings will be shared on
request.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. World Health Organization. Global update on the health sector
response to HIV. 2014. http://apps.who.int/iris/bitstream/10665/
128494/1/9789241507585_eng.pdf?ua=1
2. UNAIDS. The gap report. 2014. http://www.aidsdatahub.org/sites/
default/files/publication/UNAIDS_Gap_report_en.pdf
3. Central statistical agency. Ethiopian Demographic and Health
Survey. 2011. http://www.unicef.org/ethiopia/ET_2011_EDHS.
pdf
4. Chan KC, Wong KH, Lee SS. Universal decline in mortality in
patients with advanced HIV-1 disease in various demographic
subpopulations after the introduction of HAART in Hong Kong, from
1993 to 2002. HIV Med 2006;7:186–92.
5. FMOH. Health Sector Development Programme IV Annual
Performance Report 2013/14(1). http://www.moh.gov.et/documents/
26765/0/Annual+Perfomance+Report+2006+EFY/4f5a6b33-3ef1-
4430-a0a0-21fa13221343?version=1.0
6. Federal Ministry of Health Ethiopia. National Comprehensive HIV
Care and Treatment Training for Health care Providers Participant
Manual. 2014.
7. World Health Organization. Consolidated Guidelines On The Use
Of Antiretroviral Drugs For Treating And Preventing HIV Infection
Recommendations for a Public Health Approach. 2013. http://
apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.
pdf?ua=1
8. Johnston V, Cohen K, Wiesner L, et al. Viral suppression following
switch to secondline antiretroviral therapy: associations with
nucleoside reverse transcriptase inhibitor resistance and
subtherapeutic drug concentrations prior to switch. J Infect Dis
2014;209:711–20.
9. Jourdain G, Le Cœur S, Ngo-Giang-Huong N, et al. Switching HIV
treatment in adults based on CD4 count versus viral load monitoring:
a randomized, noninferiority trial in Thailand. PLoS Med 2013;10:
e1001494.
10. Fox MP, Shearer K, Maskew M, et al. Treatment outcomes after
seven years of public-sector HIV treatment at the Themba Lethu
clinic in Johannesburg, South Africa. AIDS 2012;26:1823–8.
11. Barth RE, Tempelman HA, Moraba R, et al. Long-term outcome of
an HIV-treatment programme in rural Africa: viral suppression
despite early mortality. AIDS Res Treat 2011;2011:434375.
12. Panos Global AIDS Programme. Antiretroviral drugs for all?
Obstacles to access to HIV/AIDS treatment. Lessons from Ethiopia,
Haiti, India, Nepal and Zambia. 2006. http://otp.unesco-ci.org/
training-resource/community-empowerment-general/antiretroviral-
drugs-all-obstacles-access-hivaids-tr
13. Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line
treatment in the Malawi antiretroviral programme: high early
mortality, but good outcomes in survivors, despite extensive drug
resistance at baseline. HIV Med 2010;11:510–18.
14. Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral
therapy: long-term outcomes in South Africa. J Acquir Immune Defic
Syndr 2012;61:158–63.
15. Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and
survival has improved, but pre-ART attrition is high in a six-year HIV
cohort data from Ethiopia. PLoS One 2010;5:e13268.
16. Wandeler G, Keiser O, Pfeiffer K, et al. Outcomes of antiretroviral
treatment programs in rural Southern Africa. J Acquir Immune Defic
Syndr 2012;59:e9–16.
17. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high
early mortality in patients on antiretroviral treatment in a rural district
of Malawi. AIDS 2006;20:2355–60.
18. Tadesse K, Haile F, Hiruy N. Predictors of mortality among patients
enrolled on antiretroviral therapy in Aksum hospital, northern
Ethiopia: a retrospective cohort study. PLoS One 2014;9:e87392.
Tsegaye AT, et al. BMJ Open 2016;6:e012537. doi:10.1136/bmjopen-2016-012537 7
Open Access
19. Liao L, Xing H, Su B, et al. Impact of HIV drug resistance on
virologic and immunologic failure and mortality in a cohort of
patients on antiretroviral therapy in China. AIDS
2013;27:1815–24.
20. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of
initial patients treated in Botswana’s National Antiretroviral Treatment
Program. AIDS 2008;22:2303–11.
21. Wandeler G, Keiser O, Mulenga L, et al. Tenofovir in second-line
ART in Zambia and South Africa: collaborative analysis of cohort
studies. J Acquir Immune Defic Syndr 2012;61:41–8.
22. Ajose O, Mookerjee S, Mills EJ, et al. Treatment outcomes of
patients on second-line antiretroviral therapy in resource-limited
settings: a systematic review and meta-analysis. AIDS
2012;26:929–38.
23. Rajasekaran S, Jeyaseelan L, Vijila S, et al. Predictors of failure of
first-line antiretroviral therapy in HIV-infected adults: Indian
experience. AIDS 2007;21(Suppl 4):S47–53.
24. Gsponer T, Petersen M, Egger M, et al. The causal effect of
switching to second-line ART in programmes without access to
routine viral load monitoring. AIDS 2012;26:57–65.
25. Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir/
r-based second-line antiretroviral treatment after 24 months of follow
up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int
AIDS Soc 2011;14:14.
26. Patel D, Desai M, Shah AN, et al. Early outcome of second line
antiretroviral therapy in treatment experienced human
immunodeficiency virus positive patients. Perspect Clin Res
2013;4:216–20.
27. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring
to guide switching antiretroviral therapy in resource-limited settings:
clinical benefits and cost effectiveness. J Acquir Immune Defic
Syndr 2010;54:258–68.
28. Nichols BE, Sigaloff KC, Kityo C, et al. Increasing the use of
second-line therapy is a cost-effective approach to prevent the
spread of drug-resistant HIV: a mathematical modelling study. J Int
AIDS Soc 2014;17:19164.
29. Assefa Y, Kiflie A, Tesfaye D, et al. Outcomes of antiretroviral
treatment program in Ethiopia: retention of patients in care is a major
challenge and varies across health facilities. BMC Health Serv Res
2011;11:81.
30. Khan S, Das M, Andries A, et al. Second-line failure and first
experience with third-line antiretroviral therapy in Mumbai, India.
Globa Health Action 2014;7:24861.
31. Long L, Fox M, Sanne I, et al. The high cost of second-line
antiretroviral therapy for HIV/AIDS in South Africa. AIDS
2010;24:915–19.
32. Dalal RP, MacPhail C, Mqhayi M, et al. Characteristics and
outcomes of adult patients lost to follow-up at an antiretroviral
treatment clinic in Johannesburg, South Africa. J Acquir Immune
Defic Syndr 2008;47:101–7.
33. Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of
antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health
2010;15:251–8.
34. Boettiger DC, Nguyen VK, Durier N, et al. Efficacy of second-line
antiretroviral therapy among people living with HIV/AIDS in Asia:
results from the TREAT Asia HIV observational database. J Acquir
Immune Defic Syndr 2015;68:186–95.
35. Siripassorn K, Manosuthi W, Chottanapund S, et al. Effectiveness of
boosted protease inhibitor-based regimens in HIV type 1-infected
patients who experienced virological failure with NNRTI-based
antiretroviral therapy in a resource-limited setting. AIDS Res Hum
Retroviruses 2010;26:139–48.
36. Pujades-Rodríguez M, Balkan S, Arnould L, et al. Treatment failure
and mortality factors in patients receiving second-line HIV therapy in
resource-limited countries. JAMA 2010;304:303–12.
37. Sigaloff KC, Hamers RL, Wallis CL, et al. Second-line antiretroviral
treatment successfully resuppresses drug-resistant HIV-1 after
first-line failure: prospective cohort in Sub-Saharan Africa. J Infect
Dis 2012;205:1739–44.
38. Court R, Leisegang R, Stewart A, et al. Short term adherence tool
predicts failure on second line protease inhibitor-based antiretroviral
therapy: an observational cohort study. BMC Infect Dis 2014;14:664.
8 Tsegaye AT, et al. BMJ Open 2016;6:e012537. doi:10.1136/bmjopen-2016-012537
Open Access
